nodes	percent_of_prediction	percent_of_DWPC	metapath
Apixaban—CYP3A5—prostate cancer	0.145	0.473	CbGaD
Apixaban—CYP2C19—prostate cancer	0.0988	0.322	CbGaD
Apixaban—CYP3A4—prostate cancer	0.0628	0.205	CbGaD
Apixaban—ABCG2—Cabazitaxel—prostate cancer	0.021	0.0444	CbGbCtD
Apixaban—ABCG2—Estrone—prostate cancer	0.0205	0.0434	CbGbCtD
Apixaban—CYP2C8—Nilutamide—prostate cancer	0.0182	0.0386	CbGbCtD
Apixaban—CYP3A5—Flutamide—prostate cancer	0.0157	0.0333	CbGbCtD
Apixaban—CYP2C19—Nilutamide—prostate cancer	0.0153	0.0324	CbGbCtD
Apixaban—CYP2C19—Bicalutamide—prostate cancer	0.0153	0.0324	CbGbCtD
Apixaban—CYP2C8—Abiraterone—prostate cancer	0.0151	0.032	CbGbCtD
Apixaban—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0141	0.0298	CbGbCtD
Apixaban—ABCG2—Conjugated Estrogens—prostate cancer	0.0134	0.0284	CbGbCtD
Apixaban—CYP2C9—Nilutamide—prostate cancer	0.0127	0.0269	CbGbCtD
Apixaban—CYP2C9—Bicalutamide—prostate cancer	0.0127	0.0269	CbGbCtD
Apixaban—CYP2C19—Flutamide—prostate cancer	0.0127	0.0268	CbGbCtD
Apixaban—ABCG2—Mitoxantrone—prostate cancer	0.0122	0.0258	CbGbCtD
Apixaban—ABCG2—Estradiol—prostate cancer	0.0118	0.0249	CbGbCtD
Apixaban—CYP1A2—Flutamide—prostate cancer	0.0117	0.0248	CbGbCtD
Apixaban—CYP3A5—Cabazitaxel—prostate cancer	0.0116	0.0246	CbGbCtD
Apixaban—ABCB1—Estramustine—prostate cancer	0.0115	0.0243	CbGbCtD
Apixaban—CYP3A5—Estrone—prostate cancer	0.0114	0.0241	CbGbCtD
Apixaban—CYP2C8—Cabazitaxel—prostate cancer	0.0112	0.0237	CbGbCtD
Apixaban—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00974	0.0206	CbGbCtD
Apixaban—CYP1A2—Estrone—prostate cancer	0.00846	0.0179	CbGbCtD
Apixaban—ABCG2—Etoposide—prostate cancer	0.00769	0.0163	CbGbCtD
Apixaban—CYP2C9—Estrone—prostate cancer	0.00762	0.0161	CbGbCtD
Apixaban—ABCB1—Cabazitaxel—prostate cancer	0.00757	0.016	CbGbCtD
Apixaban—CYP3A4—Bicalutamide—prostate cancer	0.0074	0.0157	CbGbCtD
Apixaban—ABCB1—Estrone—prostate cancer	0.0074	0.0157	CbGbCtD
Apixaban—ABCG2—Docetaxel—prostate cancer	0.00704	0.0149	CbGbCtD
Apixaban—CYP3A4—Estramustine—prostate cancer	0.00688	0.0146	CbGbCtD
Apixaban—ABCB1—Ethinyl Estradiol—prostate cancer	0.00659	0.014	CbGbCtD
Apixaban—CYP3A5—Estradiol—prostate cancer	0.00653	0.0138	CbGbCtD
Apixaban—CYP2C8—Estradiol—prostate cancer	0.00628	0.0133	CbGbCtD
Apixaban—CYP3A4—Abiraterone—prostate cancer	0.00613	0.013	CbGbCtD
Apixaban—CYP3A4—Flutamide—prostate cancer	0.00613	0.013	CbGbCtD
Apixaban—CYP2C9—Capecitabine—prostate cancer	0.00578	0.0122	CbGbCtD
Apixaban—CYP1A2—Conjugated Estrogens—prostate cancer	0.00553	0.0117	CbGbCtD
Apixaban—CYP2C19—Estradiol—prostate cancer	0.00526	0.0111	CbGbCtD
Apixaban—ABCG2—Doxorubicin—prostate cancer	0.00525	0.0111	CbGbCtD
Apixaban—CYP1A2—Estradiol—prostate cancer	0.00486	0.0103	CbGbCtD
Apixaban—ABCB1—Conjugated Estrogens—prostate cancer	0.00484	0.0102	CbGbCtD
Apixaban—CYP3A4—Cabazitaxel—prostate cancer	0.00453	0.0096	CbGbCtD
Apixaban—CYP2C19—Prednisone—prostate cancer	0.00453	0.00958	CbGbCtD
Apixaban—CYP3A4—Estrone—prostate cancer	0.00443	0.00938	CbGbCtD
Apixaban—ABCB1—Mitoxantrone—prostate cancer	0.0044	0.00931	CbGbCtD
Apixaban—CYP2C9—Estradiol—prostate cancer	0.00438	0.00927	CbGbCtD
Apixaban—CYP3A5—Etoposide—prostate cancer	0.00426	0.00902	CbGbCtD
Apixaban—ABCB1—Estradiol—prostate cancer	0.00425	0.00899	CbGbCtD
Apixaban—CYP2C8—Etoposide—prostate cancer	0.0041	0.00867	CbGbCtD
Apixaban—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00395	0.00836	CbGbCtD
Apixaban—CYP3A5—Docetaxel—prostate cancer	0.0039	0.00825	CbGbCtD
Apixaban—ABCB1—Prednisone—prostate cancer	0.00365	0.00773	CbGbCtD
Apixaban—CYP1A2—Etoposide—prostate cancer	0.00317	0.00671	CbGbCtD
Apixaban—CYP3A4—Conjugated Estrogens—prostate cancer	0.0029	0.00614	CbGbCtD
Apixaban—ABCB1—Etoposide—prostate cancer	0.00277	0.00587	CbGbCtD
Apixaban—CYP3A4—Mitoxantrone—prostate cancer	0.00264	0.00558	CbGbCtD
Apixaban—CYP3A4—Estradiol—prostate cancer	0.00255	0.00539	CbGbCtD
Apixaban—ABCB1—Docetaxel—prostate cancer	0.00254	0.00537	CbGbCtD
Apixaban—CYP3A4—Prednisone—prostate cancer	0.00219	0.00463	CbGbCtD
Apixaban—CYP2C19—urine—prostate cancer	0.00198	0.102	CbGeAlD
Apixaban—F10—prostate gland—prostate cancer	0.00194	0.0997	CbGeAlD
Apixaban—ABCB1—Doxorubicin—prostate cancer	0.00189	0.004	CbGbCtD
Apixaban—CYP3A4—Etoposide—prostate cancer	0.00166	0.00352	CbGbCtD
Apixaban—CYP1A2—urine—prostate cancer	0.00161	0.0831	CbGeAlD
Apixaban—CYP2J2—prostate gland—prostate cancer	0.00159	0.0817	CbGeAlD
Apixaban—CYP2C9—urine—prostate cancer	0.00153	0.0789	CbGeAlD
Apixaban—CYP3A4—Docetaxel—prostate cancer	0.00152	0.00322	CbGbCtD
Apixaban—F10—urethra—prostate cancer	0.0013	0.0668	CbGeAlD
Apixaban—CYP3A4—urine—prostate cancer	0.00117	0.0601	CbGeAlD
Apixaban—CYP3A4—Doxorubicin—prostate cancer	0.00113	0.0024	CbGbCtD
Apixaban—F10—testis—prostate cancer	0.000854	0.0439	CbGeAlD
Apixaban—CYP2J2—testis—prostate cancer	0.0007	0.036	CbGeAlD
Apixaban—F10—lymph node—prostate cancer	0.000619	0.0318	CbGeAlD
Apixaban—ABCG2—prostate gland—prostate cancer	0.000602	0.031	CbGeAlD
Apixaban—CYP3A5—prostate gland—prostate cancer	0.000559	0.0288	CbGeAlD
Apixaban—ABCG2—seminal vesicle—prostate cancer	0.000509	0.0262	CbGeAlD
Apixaban—CYP2C8—renal system—prostate cancer	0.000422	0.0217	CbGeAlD
Apixaban—ABCG2—urethra—prostate cancer	0.000403	0.0207	CbGeAlD
Apixaban—CYP1A2—renal system—prostate cancer	0.000395	0.0203	CbGeAlD
Apixaban—CYP3A5—renal system—prostate cancer	0.000381	0.0196	CbGeAlD
Apixaban—ABCG2—bone marrow—prostate cancer	0.00031	0.016	CbGeAlD
Apixaban—ABCB1—prostate gland—prostate cancer	0.000297	0.0153	CbGeAlD
Apixaban—CYP3A4—renal system—prostate cancer	0.000286	0.0147	CbGeAlD
Apixaban—CYP2C8—testis—prostate cancer	0.000273	0.014	CbGeAlD
Apixaban—ABCG2—testis—prostate cancer	0.000265	0.0137	CbGeAlD
Apixaban—ABCB1—seminal vesicle—prostate cancer	0.000251	0.0129	CbGeAlD
Apixaban—ABCB1—epithelium—prostate cancer	0.000218	0.0112	CbGeAlD
Apixaban—ABCB1—renal system—prostate cancer	0.000202	0.0104	CbGeAlD
Apixaban—ABCB1—urethra—prostate cancer	0.000199	0.0102	CbGeAlD
Apixaban—ABCG2—lymph node—prostate cancer	0.000192	0.00989	CbGeAlD
Apixaban—ABCB1—bone marrow—prostate cancer	0.000153	0.00787	CbGeAlD
Apixaban—ABCB1—testis—prostate cancer	0.000131	0.00673	CbGeAlD
Apixaban—Loss of consciousness—Conjugated Estrogens—prostate cancer	0.00013	0.00135	CcSEcCtD
Apixaban—Hypersensitivity—Bicalutamide—prostate cancer	0.000129	0.00134	CcSEcCtD
Apixaban—Nausea—Degarelix—prostate cancer	0.000128	0.00134	CcSEcCtD
Apixaban—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000127	0.00133	CcSEcCtD
Apixaban—Haemoglobin—Mitoxantrone—prostate cancer	0.000127	0.00133	CcSEcCtD
Apixaban—Eye disorder—Estradiol—prostate cancer	0.000127	0.00132	CcSEcCtD
Apixaban—Haemorrhage—Mitoxantrone—prostate cancer	0.000126	0.00132	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Docetaxel—prostate cancer	0.000126	0.00132	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000126	0.00131	CcSEcCtD
Apixaban—Diabetes mellitus—Prednisone—prostate cancer	0.000125	0.00131	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000125	0.0013	CcSEcCtD
Apixaban—Blood bilirubin increased—Epirubicin—prostate cancer	0.000124	0.0013	CcSEcCtD
Apixaban—Angiopathy—Estradiol—prostate cancer	0.000123	0.00128	CcSEcCtD
Apixaban—Immune system disorder—Estradiol—prostate cancer	0.000122	0.00128	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Capecitabine—prostate cancer	0.000122	0.00128	CcSEcCtD
Apixaban—Mediastinal disorder—Estradiol—prostate cancer	0.000122	0.00128	CcSEcCtD
Apixaban—Anaphylactic shock—Goserelin—prostate cancer	0.000121	0.00127	CcSEcCtD
Apixaban—Nausea—Cabazitaxel—prostate cancer	0.000121	0.00126	CcSEcCtD
Apixaban—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.00012	0.00126	CcSEcCtD
Apixaban—Rectal haemorrhage—Doxorubicin—prostate cancer	0.00012	0.00126	CcSEcCtD
Apixaban—Shock—Goserelin—prostate cancer	0.000119	0.00125	CcSEcCtD
Apixaban—Nervous system disorder—Goserelin—prostate cancer	0.000119	0.00124	CcSEcCtD
Apixaban—Thrombocytopenia—Goserelin—prostate cancer	0.000119	0.00124	CcSEcCtD
Apixaban—Shock—Conjugated Estrogens—prostate cancer	0.000118	0.00124	CcSEcCtD
Apixaban—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000118	0.00123	CcSEcCtD
Apixaban—Skin disorder—Goserelin—prostate cancer	0.000118	0.00123	CcSEcCtD
Apixaban—Skin disorder—Conjugated Estrogens—prostate cancer	0.000117	0.00122	CcSEcCtD
Apixaban—Liver function test abnormal—Docetaxel—prostate cancer	0.000116	0.00122	CcSEcCtD
Apixaban—Dizziness—Bicalutamide—prostate cancer	0.000115	0.00121	CcSEcCtD
Apixaban—Blood bilirubin increased—Doxorubicin—prostate cancer	0.000115	0.0012	CcSEcCtD
Apixaban—Melaena—Epirubicin—prostate cancer	0.000114	0.0012	CcSEcCtD
Apixaban—Breast disorder—Docetaxel—prostate cancer	0.000114	0.00119	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Docetaxel—prostate cancer	0.000114	0.00119	CcSEcCtD
Apixaban—Hypotension—Goserelin—prostate cancer	0.000113	0.00119	CcSEcCtD
Apixaban—Liver function test abnormal—Capecitabine—prostate cancer	0.000113	0.00118	CcSEcCtD
Apixaban—Hypotension—Conjugated Estrogens—prostate cancer	0.000112	0.00117	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.000111	0.00116	CcSEcCtD
Apixaban—Hepatobiliary disease—Etoposide—prostate cancer	0.000111	0.00116	CcSEcCtD
Apixaban—Breast disorder—Capecitabine—prostate cancer	0.00011	0.00115	CcSEcCtD
Apixaban—Rash—Bicalutamide—prostate cancer	0.00011	0.00115	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Capecitabine—prostate cancer	0.00011	0.00115	CcSEcCtD
Apixaban—Dermatitis—Bicalutamide—prostate cancer	0.00011	0.00115	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Prednisone—prostate cancer	0.000109	0.00114	CcSEcCtD
Apixaban—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000109	0.00114	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.000108	0.00113	CcSEcCtD
Apixaban—Ecchymosis—Epirubicin—prostate cancer	0.000106	0.00111	CcSEcCtD
Apixaban—Melaena—Doxorubicin—prostate cancer	0.000106	0.00111	CcSEcCtD
Apixaban—Syncope—Estradiol—prostate cancer	0.000106	0.00111	CcSEcCtD
Apixaban—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000104	0.00109	CcSEcCtD
Apixaban—Urinary tract disorder—Etoposide—prostate cancer	0.000104	0.00108	CcSEcCtD
Apixaban—Nausea—Bicalutamide—prostate cancer	0.000104	0.00108	CcSEcCtD
Apixaban—Loss of consciousness—Estradiol—prostate cancer	0.000104	0.00108	CcSEcCtD
Apixaban—Urethral disorder—Etoposide—prostate cancer	0.000103	0.00108	CcSEcCtD
Apixaban—Anaemia—Mitoxantrone—prostate cancer	0.000102	0.00106	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	9.97e-05	0.00104	CcSEcCtD
Apixaban—Eye disorder—Etoposide—prostate cancer	9.81e-05	0.00103	CcSEcCtD
Apixaban—Ecchymosis—Doxorubicin—prostate cancer	9.8e-05	0.00102	CcSEcCtD
Apixaban—Diabetes mellitus—Epirubicin—prostate cancer	9.78e-05	0.00102	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Epirubicin—prostate cancer	9.78e-05	0.00102	CcSEcCtD
Apixaban—Dizziness—Ethinyl Estradiol—prostate cancer	9.75e-05	0.00102	CcSEcCtD
Apixaban—Anaphylactic shock—Estradiol—prostate cancer	9.62e-05	0.00101	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Prednisone—prostate cancer	9.59e-05	0.001	CcSEcCtD
Apixaban—Angiopathy—Etoposide—prostate cancer	9.53e-05	0.000996	CcSEcCtD
Apixaban—ABCB1—lymph node—prostate cancer	9.48e-05	0.00488	CbGeAlD
Apixaban—Immune system disorder—Etoposide—prostate cancer	9.48e-05	0.000991	CcSEcCtD
Apixaban—Shock—Estradiol—prostate cancer	9.47e-05	0.00099	CcSEcCtD
Apixaban—Mediastinal disorder—Etoposide—prostate cancer	9.46e-05	0.000989	CcSEcCtD
Apixaban—Nervous system disorder—Estradiol—prostate cancer	9.44e-05	0.000987	CcSEcCtD
Apixaban—Skin disorder—Estradiol—prostate cancer	9.35e-05	0.000977	CcSEcCtD
Apixaban—Rash—Ethinyl Estradiol—prostate cancer	9.3e-05	0.000972	CcSEcCtD
Apixaban—Dermatitis—Ethinyl Estradiol—prostate cancer	9.29e-05	0.000971	CcSEcCtD
Apixaban—Hepatobiliary disease—Docetaxel—prostate cancer	9.19e-05	0.000961	CcSEcCtD
Apixaban—Epistaxis—Docetaxel—prostate cancer	9.17e-05	0.000958	CcSEcCtD
Apixaban—Diabetes mellitus—Doxorubicin—prostate cancer	9.05e-05	0.000946	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	9.05e-05	0.000946	CcSEcCtD
Apixaban—Haematuria—Capecitabine—prostate cancer	8.97e-05	0.000938	CcSEcCtD
Apixaban—Anaphylactic shock—Mitoxantrone—prostate cancer	8.97e-05	0.000937	CcSEcCtD
Apixaban—Hypersensitivity—Goserelin—prostate cancer	8.94e-05	0.000935	CcSEcCtD
Apixaban—Hepatobiliary disease—Capecitabine—prostate cancer	8.9e-05	0.00093	CcSEcCtD
Apixaban—Epistaxis—Capecitabine—prostate cancer	8.88e-05	0.000928	CcSEcCtD
Apixaban—Hypersensitivity—Conjugated Estrogens—prostate cancer	8.86e-05	0.000926	CcSEcCtD
Apixaban—Shock—Mitoxantrone—prostate cancer	8.82e-05	0.000922	CcSEcCtD
Apixaban—Thrombocytopenia—Mitoxantrone—prostate cancer	8.78e-05	0.000918	CcSEcCtD
Apixaban—Haemoglobin—Docetaxel—prostate cancer	8.77e-05	0.000917	CcSEcCtD
Apixaban—Nausea—Ethinyl Estradiol—prostate cancer	8.76e-05	0.000916	CcSEcCtD
Apixaban—Haemorrhage—Docetaxel—prostate cancer	8.73e-05	0.000912	CcSEcCtD
Apixaban—Skin disorder—Mitoxantrone—prostate cancer	8.71e-05	0.000911	CcSEcCtD
Apixaban—Urinary tract disorder—Docetaxel—prostate cancer	8.62e-05	0.000901	CcSEcCtD
Apixaban—Connective tissue disorder—Docetaxel—prostate cancer	8.57e-05	0.000896	CcSEcCtD
Apixaban—Urethral disorder—Docetaxel—prostate cancer	8.55e-05	0.000894	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Epirubicin—prostate cancer	8.51e-05	0.000889	CcSEcCtD
Apixaban—Haemoglobin—Capecitabine—prostate cancer	8.49e-05	0.000888	CcSEcCtD
Apixaban—Haemorrhage—Capecitabine—prostate cancer	8.45e-05	0.000883	CcSEcCtD
Apixaban—Anaemia—Etoposide—prostate cancer	8.45e-05	0.000883	CcSEcCtD
Apixaban—Hypotension—Mitoxantrone—prostate cancer	8.38e-05	0.000876	CcSEcCtD
Apixaban—Urinary tract disorder—Capecitabine—prostate cancer	8.34e-05	0.000872	CcSEcCtD
Apixaban—Gastrointestinal disorder—Estradiol—prostate cancer	8.31e-05	0.000869	CcSEcCtD
Apixaban—Connective tissue disorder—Capecitabine—prostate cancer	8.3e-05	0.000868	CcSEcCtD
Apixaban—Urethral disorder—Capecitabine—prostate cancer	8.28e-05	0.000866	CcSEcCtD
Apixaban—Eye disorder—Docetaxel—prostate cancer	8.15e-05	0.000852	CcSEcCtD
Apixaban—Loss of consciousness—Etoposide—prostate cancer	8.03e-05	0.00084	CcSEcCtD
Apixaban—Dizziness—Goserelin—prostate cancer	8.03e-05	0.000839	CcSEcCtD
Apixaban—Dizziness—Conjugated Estrogens—prostate cancer	7.95e-05	0.000831	CcSEcCtD
Apixaban—Angiopathy—Docetaxel—prostate cancer	7.92e-05	0.000828	CcSEcCtD
Apixaban—Eye disorder—Capecitabine—prostate cancer	7.89e-05	0.000825	CcSEcCtD
Apixaban—Immune system disorder—Docetaxel—prostate cancer	7.88e-05	0.000824	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Doxorubicin—prostate cancer	7.87e-05	0.000823	CcSEcCtD
Apixaban—Mediastinal disorder—Docetaxel—prostate cancer	7.86e-05	0.000822	CcSEcCtD
Apixaban—Liver function test abnormal—Epirubicin—prostate cancer	7.85e-05	0.000821	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	7.73e-05	0.000808	CcSEcCtD
Apixaban—Breast disorder—Epirubicin—prostate cancer	7.69e-05	0.000804	CcSEcCtD
Apixaban—Angiopathy—Capecitabine—prostate cancer	7.66e-05	0.000801	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Epirubicin—prostate cancer	7.66e-05	0.000801	CcSEcCtD
Apixaban—Rash—Goserelin—prostate cancer	7.65e-05	0.0008	CcSEcCtD
Apixaban—Dermatitis—Goserelin—prostate cancer	7.65e-05	0.0008	CcSEcCtD
Apixaban—Immune system disorder—Capecitabine—prostate cancer	7.63e-05	0.000798	CcSEcCtD
Apixaban—Mediastinal disorder—Capecitabine—prostate cancer	7.61e-05	0.000796	CcSEcCtD
Apixaban—Rash—Conjugated Estrogens—prostate cancer	7.58e-05	0.000793	CcSEcCtD
Apixaban—Dermatitis—Conjugated Estrogens—prostate cancer	7.58e-05	0.000792	CcSEcCtD
Apixaban—Haemoglobin—Prednisone—prostate cancer	7.56e-05	0.000791	CcSEcCtD
Apixaban—Haemorrhage—Prednisone—prostate cancer	7.52e-05	0.000787	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Epirubicin—prostate cancer	7.5e-05	0.000784	CcSEcCtD
Apixaban—Anaphylactic shock—Etoposide—prostate cancer	7.46e-05	0.00078	CcSEcCtD
Apixaban—Connective tissue disorder—Prednisone—prostate cancer	7.39e-05	0.000773	CcSEcCtD
Apixaban—Thrombocytopenia—Etoposide—prostate cancer	7.3e-05	0.000764	CcSEcCtD
Apixaban—Liver function test abnormal—Doxorubicin—prostate cancer	7.27e-05	0.00076	CcSEcCtD
Apixaban—Skin disorder—Etoposide—prostate cancer	7.25e-05	0.000757	CcSEcCtD
Apixaban—Nausea—Goserelin—prostate cancer	7.21e-05	0.000754	CcSEcCtD
Apixaban—Nausea—Conjugated Estrogens—prostate cancer	7.14e-05	0.000747	CcSEcCtD
Apixaban—Breast disorder—Doxorubicin—prostate cancer	7.11e-05	0.000744	CcSEcCtD
Apixaban—Hypersensitivity—Estradiol—prostate cancer	7.09e-05	0.000741	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	7.09e-05	0.000741	CcSEcCtD
Apixaban—Eye disorder—Prednisone—prostate cancer	7.03e-05	0.000735	CcSEcCtD
Apixaban—Anaemia—Docetaxel—prostate cancer	7.02e-05	0.000734	CcSEcCtD
Apixaban—Hypotension—Etoposide—prostate cancer	6.97e-05	0.000729	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Doxorubicin—prostate cancer	6.94e-05	0.000726	CcSEcCtD
Apixaban—Angiopathy—Prednisone—prostate cancer	6.83e-05	0.000714	CcSEcCtD
Apixaban—Syncope—Docetaxel—prostate cancer	6.81e-05	0.000712	CcSEcCtD
Apixaban—Anaemia—Capecitabine—prostate cancer	6.8e-05	0.000711	CcSEcCtD
Apixaban—Immune system disorder—Prednisone—prostate cancer	6.8e-05	0.000711	CcSEcCtD
Apixaban—Loss of consciousness—Docetaxel—prostate cancer	6.68e-05	0.000698	CcSEcCtD
Apixaban—Hypersensitivity—Mitoxantrone—prostate cancer	6.61e-05	0.000691	CcSEcCtD
Apixaban—Syncope—Capecitabine—prostate cancer	6.59e-05	0.000689	CcSEcCtD
Apixaban—Loss of consciousness—Capecitabine—prostate cancer	6.46e-05	0.000676	CcSEcCtD
Apixaban—Gastrointestinal disorder—Etoposide—prostate cancer	6.44e-05	0.000673	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	6.42e-05	0.000671	CcSEcCtD
Apixaban—Dizziness—Estradiol—prostate cancer	6.36e-05	0.000665	CcSEcCtD
Apixaban—Haematuria—Epirubicin—prostate cancer	6.25e-05	0.000653	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	6.22e-05	0.00065	CcSEcCtD
Apixaban—Hepatobiliary disease—Epirubicin—prostate cancer	6.2e-05	0.000648	CcSEcCtD
Apixaban—Anaphylactic shock—Docetaxel—prostate cancer	6.2e-05	0.000648	CcSEcCtD
Apixaban—Epistaxis—Epirubicin—prostate cancer	6.18e-05	0.000646	CcSEcCtD
Apixaban—Shock—Docetaxel—prostate cancer	6.1e-05	0.000638	CcSEcCtD
Apixaban—Nervous system disorder—Docetaxel—prostate cancer	6.08e-05	0.000636	CcSEcCtD
Apixaban—Thrombocytopenia—Docetaxel—prostate cancer	6.07e-05	0.000635	CcSEcCtD
Apixaban—Rash—Estradiol—prostate cancer	6.07e-05	0.000634	CcSEcCtD
Apixaban—Dermatitis—Estradiol—prostate cancer	6.06e-05	0.000634	CcSEcCtD
Apixaban—Anaemia—Prednisone—prostate cancer	6.05e-05	0.000633	CcSEcCtD
Apixaban—Skin disorder—Docetaxel—prostate cancer	6.02e-05	0.000629	CcSEcCtD
Apixaban—Haemoglobin—Epirubicin—prostate cancer	5.92e-05	0.000618	CcSEcCtD
Apixaban—Shock—Capecitabine—prostate cancer	5.9e-05	0.000617	CcSEcCtD
Apixaban—Nervous system disorder—Capecitabine—prostate cancer	5.89e-05	0.000615	CcSEcCtD
Apixaban—Haemorrhage—Epirubicin—prostate cancer	5.89e-05	0.000615	CcSEcCtD
Apixaban—Thrombocytopenia—Capecitabine—prostate cancer	5.88e-05	0.000614	CcSEcCtD
Apixaban—Syncope—Prednisone—prostate cancer	5.87e-05	0.000614	CcSEcCtD
Apixaban—Skin disorder—Capecitabine—prostate cancer	5.83e-05	0.000609	CcSEcCtD
Apixaban—Urinary tract disorder—Epirubicin—prostate cancer	5.81e-05	0.000608	CcSEcCtD
Apixaban—Hypotension—Docetaxel—prostate cancer	5.79e-05	0.000606	CcSEcCtD
Apixaban—Haematuria—Doxorubicin—prostate cancer	5.78e-05	0.000605	CcSEcCtD
Apixaban—Connective tissue disorder—Epirubicin—prostate cancer	5.78e-05	0.000605	CcSEcCtD
Apixaban—Urethral disorder—Epirubicin—prostate cancer	5.77e-05	0.000603	CcSEcCtD
Apixaban—Loss of consciousness—Prednisone—prostate cancer	5.76e-05	0.000602	CcSEcCtD
Apixaban—Hepatobiliary disease—Doxorubicin—prostate cancer	5.74e-05	0.0006	CcSEcCtD
Apixaban—Epistaxis—Doxorubicin—prostate cancer	5.72e-05	0.000598	CcSEcCtD
Apixaban—Nausea—Estradiol—prostate cancer	5.72e-05	0.000598	CcSEcCtD
Apixaban—Rash—Mitoxantrone—prostate cancer	5.65e-05	0.000591	CcSEcCtD
Apixaban—Dermatitis—Mitoxantrone—prostate cancer	5.65e-05	0.000591	CcSEcCtD
Apixaban—Hypotension—Capecitabine—prostate cancer	5.61e-05	0.000586	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.54e-05	0.000579	CcSEcCtD
Apixaban—Eye disorder—Epirubicin—prostate cancer	5.5e-05	0.000575	CcSEcCtD
Apixaban—Hypersensitivity—Etoposide—prostate cancer	5.5e-05	0.000575	CcSEcCtD
Apixaban—Haemoglobin—Doxorubicin—prostate cancer	5.47e-05	0.000572	CcSEcCtD
Apixaban—Haemorrhage—Doxorubicin—prostate cancer	5.45e-05	0.000569	CcSEcCtD
Apixaban—Urinary tract disorder—Doxorubicin—prostate cancer	5.38e-05	0.000562	CcSEcCtD
Apixaban—Gastrointestinal disorder—Docetaxel—prostate cancer	5.35e-05	0.000559	CcSEcCtD
Apixaban—Connective tissue disorder—Doxorubicin—prostate cancer	5.35e-05	0.000559	CcSEcCtD
Apixaban—Anaphylactic shock—Prednisone—prostate cancer	5.35e-05	0.000559	CcSEcCtD
Apixaban—Angiopathy—Epirubicin—prostate cancer	5.34e-05	0.000558	CcSEcCtD
Apixaban—Urethral disorder—Doxorubicin—prostate cancer	5.34e-05	0.000558	CcSEcCtD
Apixaban—Nausea—Mitoxantrone—prostate cancer	5.33e-05	0.000557	CcSEcCtD
Apixaban—Immune system disorder—Epirubicin—prostate cancer	5.32e-05	0.000556	CcSEcCtD
Apixaban—Mediastinal disorder—Epirubicin—prostate cancer	5.3e-05	0.000554	CcSEcCtD
Apixaban—Shock—Prednisone—prostate cancer	5.26e-05	0.00055	CcSEcCtD
Apixaban—Nervous system disorder—Prednisone—prostate cancer	5.24e-05	0.000548	CcSEcCtD
Apixaban—Skin disorder—Prednisone—prostate cancer	5.19e-05	0.000543	CcSEcCtD
Apixaban—Gastrointestinal disorder—Capecitabine—prostate cancer	5.18e-05	0.000542	CcSEcCtD
Apixaban—Eye disorder—Doxorubicin—prostate cancer	5.09e-05	0.000532	CcSEcCtD
Apixaban—Angiopathy—Doxorubicin—prostate cancer	4.94e-05	0.000517	CcSEcCtD
Apixaban—Dizziness—Etoposide—prostate cancer	4.93e-05	0.000516	CcSEcCtD
Apixaban—Immune system disorder—Doxorubicin—prostate cancer	4.92e-05	0.000514	CcSEcCtD
Apixaban—Mediastinal disorder—Doxorubicin—prostate cancer	4.91e-05	0.000513	CcSEcCtD
Apixaban—Anaemia—Epirubicin—prostate cancer	4.74e-05	0.000495	CcSEcCtD
Apixaban—Rash—Etoposide—prostate cancer	4.7e-05	0.000492	CcSEcCtD
Apixaban—Dermatitis—Etoposide—prostate cancer	4.7e-05	0.000491	CcSEcCtD
Apixaban—Syncope—Epirubicin—prostate cancer	4.59e-05	0.00048	CcSEcCtD
Apixaban—Hypersensitivity—Docetaxel—prostate cancer	4.57e-05	0.000477	CcSEcCtD
Apixaban—Loss of consciousness—Epirubicin—prostate cancer	4.5e-05	0.000471	CcSEcCtD
Apixaban—Nausea—Etoposide—prostate cancer	4.43e-05	0.000463	CcSEcCtD
Apixaban—Hypersensitivity—Capecitabine—prostate cancer	4.42e-05	0.000462	CcSEcCtD
Apixaban—Anaemia—Doxorubicin—prostate cancer	4.38e-05	0.000458	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.33e-05	0.000453	CcSEcCtD
Apixaban—Syncope—Doxorubicin—prostate cancer	4.25e-05	0.000444	CcSEcCtD
Apixaban—Anaphylactic shock—Epirubicin—prostate cancer	4.18e-05	0.000437	CcSEcCtD
Apixaban—Loss of consciousness—Doxorubicin—prostate cancer	4.17e-05	0.000436	CcSEcCtD
Apixaban—Shock—Epirubicin—prostate cancer	4.11e-05	0.00043	CcSEcCtD
Apixaban—Nervous system disorder—Epirubicin—prostate cancer	4.1e-05	0.000429	CcSEcCtD
Apixaban—Dizziness—Docetaxel—prostate cancer	4.1e-05	0.000429	CcSEcCtD
Apixaban—Thrombocytopenia—Epirubicin—prostate cancer	4.09e-05	0.000428	CcSEcCtD
Apixaban—Skin disorder—Epirubicin—prostate cancer	4.06e-05	0.000425	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.01e-05	0.000419	CcSEcCtD
Apixaban—Dizziness—Capecitabine—prostate cancer	3.97e-05	0.000415	CcSEcCtD
Apixaban—Hypersensitivity—Prednisone—prostate cancer	3.94e-05	0.000412	CcSEcCtD
Apixaban—Rash—Docetaxel—prostate cancer	3.91e-05	0.000409	CcSEcCtD
Apixaban—Hypotension—Epirubicin—prostate cancer	3.91e-05	0.000408	CcSEcCtD
Apixaban—Dermatitis—Docetaxel—prostate cancer	3.9e-05	0.000408	CcSEcCtD
Apixaban—Anaphylactic shock—Doxorubicin—prostate cancer	3.87e-05	0.000404	CcSEcCtD
Apixaban—Shock—Doxorubicin—prostate cancer	3.81e-05	0.000398	CcSEcCtD
Apixaban—Nervous system disorder—Doxorubicin—prostate cancer	3.79e-05	0.000397	CcSEcCtD
Apixaban—Thrombocytopenia—Doxorubicin—prostate cancer	3.79e-05	0.000396	CcSEcCtD
Apixaban—Rash—Capecitabine—prostate cancer	3.78e-05	0.000396	CcSEcCtD
Apixaban—Dermatitis—Capecitabine—prostate cancer	3.78e-05	0.000395	CcSEcCtD
Apixaban—Skin disorder—Doxorubicin—prostate cancer	3.76e-05	0.000393	CcSEcCtD
Apixaban—Nausea—Docetaxel—prostate cancer	3.68e-05	0.000385	CcSEcCtD
Apixaban—Hypotension—Doxorubicin—prostate cancer	3.62e-05	0.000378	CcSEcCtD
Apixaban—Gastrointestinal disorder—Epirubicin—prostate cancer	3.61e-05	0.000377	CcSEcCtD
Apixaban—Nausea—Capecitabine—prostate cancer	3.56e-05	0.000373	CcSEcCtD
Apixaban—Dizziness—Prednisone—prostate cancer	3.54e-05	0.00037	CcSEcCtD
Apixaban—Rash—Prednisone—prostate cancer	3.37e-05	0.000352	CcSEcCtD
Apixaban—Dermatitis—Prednisone—prostate cancer	3.37e-05	0.000352	CcSEcCtD
Apixaban—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.34e-05	0.000349	CcSEcCtD
Apixaban—Nausea—Prednisone—prostate cancer	3.18e-05	0.000332	CcSEcCtD
Apixaban—Hypersensitivity—Epirubicin—prostate cancer	3.08e-05	0.000322	CcSEcCtD
Apixaban—Hypersensitivity—Doxorubicin—prostate cancer	2.85e-05	0.000298	CcSEcCtD
Apixaban—Dizziness—Epirubicin—prostate cancer	2.76e-05	0.000289	CcSEcCtD
Apixaban—Rash—Epirubicin—prostate cancer	2.64e-05	0.000276	CcSEcCtD
Apixaban—Dermatitis—Epirubicin—prostate cancer	2.63e-05	0.000275	CcSEcCtD
Apixaban—Dizziness—Doxorubicin—prostate cancer	2.56e-05	0.000267	CcSEcCtD
Apixaban—Nausea—Epirubicin—prostate cancer	2.48e-05	0.00026	CcSEcCtD
Apixaban—Rash—Doxorubicin—prostate cancer	2.44e-05	0.000255	CcSEcCtD
Apixaban—Dermatitis—Doxorubicin—prostate cancer	2.44e-05	0.000255	CcSEcCtD
Apixaban—Nausea—Doxorubicin—prostate cancer	2.3e-05	0.00024	CcSEcCtD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.19e-06	2.07e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—HPGDS—prostate cancer	2.18e-06	2.06e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.18e-06	2.06e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ABCG5—prostate cancer	2.18e-06	2.06e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—TH—prostate cancer	2.17e-06	2.05e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP2C19—prostate cancer	2.17e-06	2.05e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP1B1—prostate cancer	2.17e-06	2.05e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CREBBP—prostate cancer	2.15e-06	2.03e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP3A4—prostate cancer	2.15e-06	2.03e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.14e-06	2.02e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.13e-06	2.02e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTA1—prostate cancer	2.13e-06	2.01e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CYP1A1—prostate cancer	2.12e-06	2.01e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—COMT—prostate cancer	2.12e-06	2e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTT1—prostate cancer	2.12e-06	2e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ACHE—prostate cancer	2.12e-06	2e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP1B1—prostate cancer	2.11e-06	2e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GSTP1—prostate cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTO1—prostate cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NAT2—prostate cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—ERCC2—prostate cancer	2.11e-06	1.99e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GGT1—prostate cancer	2.1e-06	1.98e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP2A6—prostate cancer	2.09e-06	1.98e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.09e-06	1.97e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.08e-06	1.97e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—ITPR1—prostate cancer	2.08e-06	1.96e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NCOA1—prostate cancer	2.07e-06	1.95e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NQO1—prostate cancer	2.06e-06	1.95e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GGT1—prostate cancer	2.05e-06	1.93e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.04e-06	1.93e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PIK3CD—prostate cancer	2.04e-06	1.93e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—AKR1C3—prostate cancer	2.04e-06	1.92e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP19A1—prostate cancer	2.04e-06	1.92e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—TH—prostate cancer	2.03e-06	1.92e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PRKACB—prostate cancer	2.03e-06	1.91e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—LRP2—prostate cancer	2.02e-06	1.91e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PLCB2—prostate cancer	2.02e-06	1.91e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.02e-06	1.91e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.02e-06	1.91e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NCOA1—prostate cancer	2.02e-06	1.91e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.01e-06	1.9e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP17A1—prostate cancer	2e-06	1.89e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2e-06	1.89e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP19A1—prostate cancer	1.99e-06	1.88e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—P4HB—prostate cancer	1.98e-06	1.87e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—MTHFR—prostate cancer	1.98e-06	1.87e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.98e-06	1.87e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.97e-06	1.87e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—RXRA—prostate cancer	1.96e-06	1.86e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—TYMS—prostate cancer	1.96e-06	1.85e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PPARA—prostate cancer	1.94e-06	1.83e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GSTM1—prostate cancer	1.94e-06	1.83e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.93e-06	1.82e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—NOS3—prostate cancer	1.93e-06	1.82e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—RXRA—prostate cancer	1.92e-06	1.81e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GGT1—prostate cancer	1.91e-06	1.81e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.91e-06	1.81e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NCOA2—prostate cancer	1.91e-06	1.81e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—LPL—prostate cancer	1.9e-06	1.8e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—COMT—prostate cancer	1.89e-06	1.79e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTP1—prostate cancer	1.88e-06	1.78e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NCOA1—prostate cancer	1.88e-06	1.78e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.88e-06	1.78e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.86e-06	1.75e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—ITPR1—prostate cancer	1.85e-06	1.75e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—MED12—prostate cancer	1.85e-06	1.75e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—COMT—prostate cancer	1.85e-06	1.75e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTP1—prostate cancer	1.84e-06	1.74e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.84e-06	1.74e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GNG5—prostate cancer	1.83e-06	1.73e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CAV1—prostate cancer	1.83e-06	1.72e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—ERCC2—prostate cancer	1.82e-06	1.72e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.82e-06	1.72e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.82e-06	1.72e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—ITPR1—prostate cancer	1.81e-06	1.71e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—RXRA—prostate cancer	1.79e-06	1.69e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.78e-06	1.68e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PIK3CB—prostate cancer	1.78e-06	1.68e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NCOA3—prostate cancer	1.77e-06	1.67e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PTGS2—prostate cancer	1.76e-06	1.66e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NQO1—prostate cancer	1.76e-06	1.66e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—TYMS—prostate cancer	1.75e-06	1.66e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.74e-06	1.65e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—TH—prostate cancer	1.73e-06	1.64e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTM1—prostate cancer	1.73e-06	1.64e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—COMT—prostate cancer	1.73e-06	1.63e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.72e-06	1.63e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTP1—prostate cancer	1.72e-06	1.62e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.72e-06	1.62e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—MTHFR—prostate cancer	1.71e-06	1.62e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—TYMS—prostate cancer	1.71e-06	1.62e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.71e-06	1.61e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—LPL—prostate cancer	1.7e-06	1.61e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—ITPR1—prostate cancer	1.69e-06	1.6e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTM1—prostate cancer	1.69e-06	1.6e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.69e-06	1.59e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—HPGDS—prostate cancer	1.69e-06	1.59e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PPARA—prostate cancer	1.68e-06	1.59e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.67e-06	1.58e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PIK3CG—prostate cancer	1.66e-06	1.57e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.66e-06	1.57e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—LPL—prostate cancer	1.66e-06	1.57e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.64e-06	1.55e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ACHE—prostate cancer	1.63e-06	1.54e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTT1—prostate cancer	1.63e-06	1.54e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GGT1—prostate cancer	1.63e-06	1.54e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—ERCC2—prostate cancer	1.63e-06	1.54e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.62e-06	1.53e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NCOA1—prostate cancer	1.61e-06	1.52e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP1A1—prostate cancer	1.6e-06	1.51e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—TYMS—prostate cancer	1.6e-06	1.51e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—ERCC2—prostate cancer	1.59e-06	1.5e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.59e-06	1.5e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CAV1—prostate cancer	1.58e-06	1.49e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTM1—prostate cancer	1.58e-06	1.49e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—INS—prostate cancer	1.57e-06	1.49e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.57e-06	1.49e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PRKACB—prostate cancer	1.56e-06	1.48e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—LPL—prostate cancer	1.55e-06	1.46e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.55e-06	1.46e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CREBBP—prostate cancer	1.54e-06	1.46e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PTEN—prostate cancer	1.54e-06	1.45e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—RXRA—prostate cancer	1.53e-06	1.45e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—MTHFR—prostate cancer	1.53e-06	1.45e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.51e-06	1.43e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PPARA—prostate cancer	1.5e-06	1.42e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.5e-06	1.41e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—MTHFR—prostate cancer	1.49e-06	1.41e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.49e-06	1.41e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—ERCC2—prostate cancer	1.48e-06	1.4e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—COMT—prostate cancer	1.47e-06	1.39e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NCOA2—prostate cancer	1.47e-06	1.39e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTP1—prostate cancer	1.47e-06	1.39e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—EP300—prostate cancer	1.47e-06	1.38e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PPARA—prostate cancer	1.47e-06	1.38e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.46e-06	1.38e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ITPR1—prostate cancer	1.44e-06	1.36e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.44e-06	1.36e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.42e-06	1.34e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CAV1—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.41e-06	1.33e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—MTHFR—prostate cancer	1.4e-06	1.32e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—NOS3—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CAV1—prostate cancer	1.38e-06	1.3e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.37e-06	1.3e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PPARA—prostate cancer	1.37e-06	1.29e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—TYMS—prostate cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—INS—prostate cancer	1.36e-06	1.29e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NQO1—prostate cancer	1.36e-06	1.28e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTM1—prostate cancer	1.35e-06	1.27e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.35e-06	1.27e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—TH—prostate cancer	1.34e-06	1.26e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CREBBP—prostate cancer	1.34e-06	1.26e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—LPL—prostate cancer	1.32e-06	1.25e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.3e-06	1.23e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CAV1—prostate cancer	1.29e-06	1.22e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.29e-06	1.21e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.28e-06	1.21e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ERCC2—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PTGS2—prostate cancer	1.26e-06	1.19e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GGT1—prostate cancer	1.26e-06	1.19e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PIK3CG—prostate cancer	1.25e-06	1.19e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NCOA1—prostate cancer	1.24e-06	1.17e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.23e-06	1.16e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.22e-06	1.16e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—INS—prostate cancer	1.22e-06	1.15e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—NOS3—prostate cancer	1.2e-06	1.13e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—MTHFR—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CREBBP—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—INS—prostate cancer	1.19e-06	1.12e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—RXRA—prostate cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.17e-06	1.11e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PPARA—prostate cancer	1.17e-06	1.11e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CREBBP—prostate cancer	1.16e-06	1.1e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—COMT—prostate cancer	1.14e-06	1.08e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTP1—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.13e-06	1.07e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ITPR1—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—INS—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PIK3CD—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PTEN—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CAV1—prostate cancer	1.1e-06	1.04e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PTGS2—prostate cancer	1.09e-06	1.03e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CREBBP—prostate cancer	1.09e-06	1.03e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PIK3CA—prostate cancer	1.08e-06	1.02e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NOS3—prostate cancer	1.07e-06	1.01e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—TYMS—prostate cancer	1.05e-06	9.95e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.05e-06	9.93e-06	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—EP300—prostate cancer	1.05e-06	9.92e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NOS3—prostate cancer	1.04e-06	9.84e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTM1—prostate cancer	1.04e-06	9.84e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.03e-06	9.74e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—LPL—prostate cancer	1.02e-06	9.66e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PIK3CG—prostate cancer	1e-06	9.46e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.87e-07	9.33e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PIK3CB—prostate cancer	9.85e-07	9.31e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ERCC2—prostate cancer	9.79e-07	9.25e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PTGS2—prostate cancer	9.76e-07	9.22e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NOS3—prostate cancer	9.73e-07	9.19e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PIK3CB—prostate cancer	9.61e-07	9.08e-06	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PTEN—prostate cancer	9.54e-07	9.01e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PTGS2—prostate cancer	9.53e-07	9e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—INS—prostate cancer	9.48e-07	8.96e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CREBBP—prostate cancer	9.29e-07	8.78e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—MTHFR—prostate cancer	9.2e-07	8.69e-06	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—EP300—prostate cancer	9.09e-07	8.59e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PPARA—prostate cancer	9.03e-07	8.53e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PIK3CB—prostate cancer	8.98e-07	8.49e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PTGS2—prostate cancer	8.9e-07	8.41e-06	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—AKT1—prostate cancer	8.86e-07	8.37e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PIK3CD—prostate cancer	8.8e-07	8.32e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PTEN—prostate cancer	8.51e-07	8.04e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CAV1—prostate cancer	8.49e-07	8.02e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NOS3—prostate cancer	8.31e-07	7.86e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PTEN—prostate cancer	8.31e-07	7.85e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—EP300—prostate cancer	8.12e-07	7.67e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—EP300—prostate cancer	7.92e-07	7.49e-06	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PIK3CA—prostate cancer	7.77e-07	7.34e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PTEN—prostate cancer	7.76e-07	7.33e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.73e-07	7.3e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PIK3CB—prostate cancer	7.67e-07	7.25e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PTGS2—prostate cancer	7.6e-07	7.19e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—EP300—prostate cancer	7.4e-07	6.99e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—INS—prostate cancer	7.32e-07	6.91e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CREBBP—prostate cancer	7.17e-07	6.77e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.8e-07	6.42e-06	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PIK3CA—prostate cancer	6.73e-07	6.36e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PTEN—prostate cancer	6.63e-07	6.27e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NOS3—prostate cancer	6.42e-07	6.06e-06	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—AKT1—prostate cancer	6.34e-07	6e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—EP300—prostate cancer	6.32e-07	5.98e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PIK3CA—prostate cancer	6e-07	5.67e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.92e-07	5.6e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PTGS2—prostate cancer	5.87e-07	5.55e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PIK3CA—prostate cancer	5.86e-07	5.54e-06	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—AKT1—prostate cancer	5.5e-07	5.19e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.47e-07	5.17e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PTEN—prostate cancer	5.12e-07	4.84e-06	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—AKT1—prostate cancer	4.91e-07	4.64e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—EP300—prostate cancer	4.88e-07	4.61e-06	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—AKT1—prostate cancer	4.79e-07	4.52e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PIK3CA—prostate cancer	4.68e-07	4.42e-06	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—AKT1—prostate cancer	4.47e-07	4.23e-06	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—AKT1—prostate cancer	3.82e-07	3.61e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.61e-07	3.41e-06	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—AKT1—prostate cancer	2.95e-07	2.79e-06	CbGpPWpGaD
